Authors
Latest:
Cristian on the 2023 Miami Cancer Institute Oncology Rehabilitation SymposiumAdrian Cristian, MD, discusses the background of the third annual Miami Cancer Institute Oncology Rehabilitation Symposium and provides an overview of some of the topics that were presented this year.
Latest:
Beyond the First-Line: Economides on Advancing Therapies in RCCIn our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Latest:
Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive CareIn contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.
Latest:
Timing of MRD Testing in Lung Cancer Affects Patient OutcomesOleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.
Latest:
Bispecific Antibodies Look Promising in Follicular LymphomaThe use of bispecific antibodies has the potential to revolutionize the management of FL.
Latest:
Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLCMasahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
MRD Linked to Long-Term Survival With Azacitidine Therapy in AMLAndrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Latest:
Exploring Innovations in Lymphoma Treatment With Russler-GermainDavid A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
Latest:
Advancing Thyroid Cancer Care: Molecular Testing & Targeted TherapiesNoah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.
Latest:
Future Directions for NK Cell Platforms in Hematologic MalignanciesJeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
Latest:
Manipulating T Cells to Treat Patients With CancerBruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Exploring Novel Combinations in Indolent LymphomasAlthough chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Latest:
Navigating Unmet Needs in SR/D cGvHDDr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Latest:
What’s Next for the HER2-Negative Breast Cancer Space?Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
Latest:
Next Steps in the Development of AxatilimabCorey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.
Latest:
CAR T and Bispecifics Take Center Stage in New Myeloma TrialsAdam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.
Latest:
Areas of Growth in the Management of EGFR-Mutated Lung CancerLiza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Insights on Offering BsAbs in a Community Setting ContinuedJohn M. Burke, MD, shares his tips for offering bispecific antibody therapy in a community setting.
Latest:
Disparities in Access to CAR T-Cell Therapy for Patients With CancerLindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.
Latest:
Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLCFiras B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.
Latest:
Exploring the Use of Orca-T for Patients With Acute and Chronic GVHDMehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Latest:
World Cancer Day: Next Generation Sequencing at the Forefront of Precision MedicineNext generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.
Latest:
Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCCMilind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.
Latest:
Next Steps for Finding Optimal Role for Adjuvant RCC TherapyEric A. Singer, MD, MS, discusses future developments that could improve the utilization of adjuvant therapy for high-risk renal cell carcinoma.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Fazal on Modalities to Lower the Risk of Acute and Chronic GVHDSalman Fazal, MD, discusses acute and chronic graft-versus-host-disease and younger match unrelated donor transplant for patients with cancer.
Latest:
Targeted Therapy With Tafasitamab Proves Effective in DLBCLHayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.
Latest:
Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast CancerCharles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.
